Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03287245 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | terminated | Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 4 | Dec 8, 2021 | clinicaltrials |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia(PAC326) | terminated | Phase 3 | 311 | CTI BioPharmaINDUSTRY | 12 | Nov 18, 2021 |
| clinicaltrials |
| NCT02660281 | URMC Related Haplo-identical Donor BMT(HaploOnly) | completed | Phase 1 | 74 | University of RochesterOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01731951 | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | completed | Phase 2 | 80 | Geron CorporationINDUSTRY | 1 | Sep 21, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01814475 | Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis(GITMO-MF2010) | completed | Phase 2 | 62 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT03065400 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | completed | Phase 2 | 10 | John MascarenhasOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT02530619 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | unknown | N/A | 26 | Northwestern UniversityOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 4, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02912884 | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure(MPNClot) | completed | — | 80 | Dr Yan BeauverdOTHER | 2 | Nov 10, 2020 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | terminated | N/A | 3 | Hamad Medical CorporationINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT01369498 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | completed | Phase 2 | 54 | Gilead SciencesINDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02823184 | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms(PhiNESS) | completed | — | 148 | University Hospital, BordeauxOTHER | 1 | Jun 19, 2020 | clinicaltrials |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01998828 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 39 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Apr 20, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT03907436 | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase(NUTRIENT) | completed | N/A | 30 | University of California, IrvineOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT00397813 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02435550 | iCare for Cancer Patients | terminated | N/A | 136 | University of FloridaOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03745378 | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)(MPN-K) | completed | — | 1,881 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 6 | Dec 6, 2019 | clinicaltrials |
| NCT00463385 | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia | completed | Phase 2 | 88 | CelgeneINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT00928707 | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera(PV) | completed | Phase 2 | 45 | ItalfarmacoINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00715247 | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | completed | — | 726 | University of UtahOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02407080 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | completed | Phase 1 | 13 | John MascarenhasOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00997386 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States(ALBUM) | completed | Phase 2 | 16 | University of ArizonaOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT01417520 | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease | completed | — | 88 | National Human Genome Research Institute (NHGRI)NIH | 1 | Jul 26, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2021source: clinicaltrials